Clarfeld Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Clarfeld Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$9K	Buy	+56	New	+$9.7K	0.01%	252

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Clarfeld Financial Advisors's VRTX Position: Q4 2018 in Review

Clarfeld Financial Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2018: 56 shares worth $9K. The stake represents 0.01% of the portfolio and ranks #252 among its holdings.

706 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.

Clarfeld Financial Advisors held 56 shares of Vertex Pharmaceuticals worth $9K as of Q4 2018.
Vertex Pharmaceuticals was a new Clarfeld Financial Advisors position in Q4 2018.
Vertex Pharmaceuticals made up 0.01% of Clarfeld Financial Advisors's portfolio in Q4 2018, its #252 holding.
706 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.

Based on Clarfeld Financial Advisors's 13F filing for Q4 2018, filed 15 Feb 2019.